Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the ...

Tirzepatide linked to more GI issues than semaglutide in new study on weight-loss drugs without diabetes. Read more!

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

We want you to take advantage of everything Clinical Advisor has to offer. To view unlimited content, log in or register for free.

Jaime Almandoz, MD, MBA, of UT Southwestern Medical Center, speaks on results of a study that investigated tirzepatide uptake ...

GLP-1 medications like Semaglutide, Tirzepatide, and even oral options that target key metabolic processes. TMatesis positioning itself as a go-to provider in this space, offering affordable ...

Compounded drugs are custom-made and unbranded medications that contain the same active ingredient as a marketed drug, such as semaglutide or tirzepatide, pursuant to a prescription. A shortage of ...

Semaglutide and tirzepatide prescriptions within Epic-affiliated health care systems increased slightly between 2021 and 2024, but their uptake remained limited, with only 3% of eligible patients ...

systems in the U.S. Only 2.3% of over 39 million eligible adults received prescriptions for semaglutide or tirzepatide (Mounjaro, Zepbound) for obesity between 2021 and 2024. (JAMA) Eli Lilly is ...